评估STEMI患者的长期结果与新左捆分支区块:可修改风险因素的影响
Larisa Anghel1,2, Bogdan-Sorin Tudurachi1,2, Andreea Tudurachi2
1Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700503 Iași, Romania.
Journal of personalized medicine
|July 27, 2024
概括
有效地管理可改变的风险因素,如吸烟和脂质失调,对于改善ST段升高心肌梗塞 (STEMI) 后的结果至关重要,特别是在左捆支部阻塞 (LBBB) 患者中.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 公共卫生 公共卫生
背景情况:
- 冠状动脉疾病仍然是全球主要的死亡原因,需要对可修改的心血管风险因素进行早期干预.
- 有效管理风险因素对于预防复发性冠状动脉事件和改善患者的治疗结果至关重要.
研究的目的:
- 评估ST段升高心肌梗塞 (STEMI) 患者可修改心血管风险因素的长期管理.
- 为了比较STEMI患者的风险因素管理和结果,新发病的左捆分支区块 (LBBB) 与没有LBBB的患者相比.
主要方法:
- 在罗马尼亚一家高等学术医院对387名STEMI患者的前性分析 (2011-2013).
- 对STEMI患者新发性LBBB与没有LBBB的匹配对照组进行比较.
- 长期随访 (LBBB的中位数为9.6年,非LBBB的9.2年) 评估风险因素的流行和管理.
主要成果:
- 吸烟,肥胖和脂质失调在两组的基线上都非常普遍.
- 在LBBB组观察到显著的吸烟减少 (73.80%至61.90%).
- 与对照组相比,LBBB患者更频繁地达到低密度脂蛋白胆固醇 (LDLc) 目标 (71.42%至59.52%).
- 随访后,在两组中,他类药物的使用显著下降.
- 在两组中都发现了脱脂症和吸烟之间强烈的正相关性,随后在两组中都出现了冠状动脉再注射.
结论:
- 针对性地治疗脱脂症和戒烟对于改善STEMI后冠状动脉再输血至关重要.
- 这些干预措施对于STEMI患者具有诸如LBBB等复杂因素尤其重要.
- 长期坚持风险因素管理策略需要进一步关注.
更多相关视频
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.3K
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
24.2K
相关概念视频
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
